Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20424472 | 0.88 | DRD4 (0.55) | PARP1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL4295364 | 0.87 | PARP1 (0.65) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL10923540 | 0.87 | PARP1 (0.69) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL16421393 | 0.87 | PARP1 (0.65) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL3087984 | 0.83 | PARP1 (0.64) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL10642401 | 0.83 | PARP1 (0.60) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL9130576 | 0.83 | PARP1 (0.60) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL554735 | 0.83 | PARP1 (0.72) | PARP1ALDH1A1MAPTMMP12PKM | |
| SCHEMBL11002313 | 0.83 | PARP1 (0.77) | PARP1ALDH1A1MAPTMMP12DRD2 | |
| SCHEMBL4767159 | 0.82 | PARP1 (0.59) | PARP1ALDH1A1MAPTMMP12PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| CN-116554050-A | Amide phenol derivative and application thereof | 四川大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-114874201-B | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-114874201-A | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | disclosed |
| EP-0670318-A2 | Acetamides with analgesic and neuroprotective activity | MERCK PATENT GmbH (DE) | 1995-09-06 | — | — | EP | disclosed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | PARP1 1951/4885ALDH1A1 3435/4885MAPT 1301/4885 |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | PARP1 3700/4885ALDH1A1 118/4885MAPT 3199/4885 |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | PARP1 699/4885ALDH1A1 1569/4885MAPT 4420/4885 |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | PARP1 4875/4885ALDH1A1 2708/4885MAPT 4442/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | PARP1 320/4885ALDH1A1 280/4885MAPT 3061/4885 |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | OPRK1, OPRL1, OPRD1 | PARP1 2215/4885ALDH1A1 786/4885MAPT 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.